{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:56:04Z","timestamp":1791309364715,"version":"4.3.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ctrv.2024.102751","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T21:58:16Z","timestamp":1714773496000},"page":"102751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"special_numbering":"C","title":["Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations"],"prefix":"10.1016","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9857-6953","authenticated-orcid":false,"given":"Layal","family":"Rached","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Laparra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madona","family":"Sakkal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Xavier","family":"Danlos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Barlesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Carbonnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"De Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Even","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Le Pavec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Michot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"M. Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Scotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Ponce Aix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lambotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Capucine","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Champiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctrv.2024.102751_b0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41416-018-0294-4","article-title":"PD-Loma: a cancer entity with a shared sensitivity to the PD-1\/PD-L1 pathway blockade","volume":"120","author":"Hirsch","year":"2019","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102751_b0010","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102751_b0015","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/d41573-019-00182-w","article-title":"Trends in clinical development for PD-1\/PD-L1 inhibitors","volume":"19","author":"Xin","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102751_b0020","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102751_b0025","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.immuni.2018.03.007","article-title":"Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies","volume":"48","author":"Patel","year":"2018","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102751_b0030","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":"5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.ctrv.2024.102751_b0035","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1158\/1078-0432.CCR-15-2584","article-title":"HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma","volume":"22","author":"Zheng","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102751_b0040","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The principles of engineering immune cells to treat cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102751_b0045","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","article-title":"Combination strategies to maximize the benefits of cancer immunotherapy","volume":"14","author":"Zhu","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102751_b0050","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.4049\/jimmunol.170.10.4905","article-title":"Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells","volume":"170","author":"Nowak","year":"2003","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102751_b0055","first-page":"2353","article-title":"Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy","volume":"62","author":"Nowak","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102751_b0060","unstructured":"Awwad M, North RJ. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells. :6."},{"key":"10.1016\/j.ctrv.2024.102751_b0065","doi-asserted-by":"crossref","unstructured":"Lutsiak MEC, Semnani RT, Pascalis RD, Kashmiri SVS, Schlom J, Sabzevari H. Inhibition of CD4\u03e925\u03e9 T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. 2005;105(7):7.","DOI":"10.1182\/blood-2004-06-2410"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102751_b0070","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1111\/jcmm.14356","article-title":"Immunogenic cell death in cancer therapy: Present and emerging inducers","volume":"23","author":"Zhou","year":"2019","journal-title":"J Cell Mol Med"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102751_b0075","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cellimm.2010.02.007","article-title":"Consecutive low doses of cyclophosphamide preferentially target Tregs and potentiate T cell responses induced by DNA PLG microparticle immunization","volume":"262","author":"Barbon","year":"2010","journal-title":"Cell Immunol"},{"key":"10.1016\/j.ctrv.2024.102751_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01680","article-title":"The new era of cancer immunotherapy: targeting myeloid-derived suppressor cells to overcome immune evasion","author":"De Cicco","year":"2020","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.ctrv.2024.102751_b0085","unstructured":"Nowak AK, Robinson BWS, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy."},{"key":"10.1016\/j.ctrv.2024.102751_b0090","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.biocel.2018.03.004","article-title":"HDAC inhibitors as epigenetic regulators for cancer immunotherapy","volume":"98","author":"Conte","year":"2018","journal-title":"Int J Biochem Cell Biol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102751_b0095","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102751_b0100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","author":"Schneider","year":"2021","journal-title":"Journal of Clinical Oncology."},{"issue":"6","key":"10.1016\/j.ctrv.2024.102751_b0105","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.cell.2021.02.011","article-title":"Understanding and treating the inflammatory adverse events of cancer immunotherapy","volume":"184","author":"Dougan","year":"2021","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102751_b0110","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(14)70006-3","article-title":"Guidance on the management of diarrhoea during cancer chemotherapy","volume":"15","author":"Andreyev","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102751_b0115","doi-asserted-by":"crossref","DOI":"10.1200\/OP.20.00002","article-title":"Immune checkpoint inhibitor\u2013mediated diarrhea and colitis: a clinical review","author":"Gong","year":"2020","journal-title":"JCO Oncology Practice."},{"key":"10.1016\/j.ctrv.2024.102751_b0120","article-title":"Gut microbiota modulation of efficacy and toxicity of cancer chemotherapy and immunotherapy","author":"Chrysostomou","year":"2022","journal-title":"Gastroenterology."},{"issue":"2","key":"10.1016\/j.ctrv.2024.102751_b0125","first-page":"95","article-title":"Hepatotoxicity secondary to chemotherapy","volume":"2","author":"Grigorian","year":"2014","journal-title":"J Clin Transl Hepatol"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102751_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2020.100170","article-title":"Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors","volume":"2","author":"De Martin","year":"2020","journal-title":"JHEP Reports"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102751_b0135","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1053\/j.semdp.2019.07.009","article-title":"Checkpoint inhibitor-induced liver injury: A novel form of liver disease emerging in the era of cancer immunotherapy","volume":"36","author":"Zen","year":"2019","journal-title":"Semin Diagn Pathol"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102751_b0140","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2217\/imt-2018-0186","article-title":"Toxicity patterns associated with chemotherapy\/immune checkpoint inhibitor combinations: a meta-analysis","volume":"11","author":"Abdel-Rahman","year":"2019","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ctrv.2024.102751_b0145","doi-asserted-by":"crossref","first-page":"101535","DOI":"10.1016\/j.eclinm.2022.101535","article-title":"Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system","volume":"50","author":"Yan","year":"2022","journal-title":"eClinicalMedicine."},{"key":"10.1016\/j.ctrv.2024.102751_b0150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.760737","article-title":"A network comparison on safety profiling of immune checkpoint inhibitors in advanced lung cancer","volume":"12","author":"Yan","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2024.102751_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103223","article-title":"Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials","volume":"159","author":"Tarantino","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2024.102751_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108790","article-title":"Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis","volume":"109","author":"Li","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ctrv.2024.102751_b0165","article-title":"Article commentary: patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs)","volume":"6","author":"Weldring","year":"2013","journal-title":"Health Serv Insights"},{"key":"10.1016\/j.ctrv.2024.102751_b0170","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejca.2020.02.010","article-title":"The 2016\u20132019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study","volume":"130","author":"Michot","year":"2020","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102751_b0175","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2024.102751_b0180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front Immunol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224000793?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224000793?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T13:46:04Z","timestamp":1716385564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737224000793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":36,"alternative-id":["S0305737224000793"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102751","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102751","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102751"}}